Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study is to compare the two cardioplegia solutions (blood cardioplegia by means of MPS ® vs. Cardioplexol ®) regarding perioperative outcome and with special attention to cardiac markers in patients with a recent heart attack.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental | bypass surgery with blood cardioplegia by means of MPS |
| |
| Active Comparator | bypass surgery with blood cardioplegia by means of Cardioplexol ® |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Myocardial protection system (MPS) | Other | cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used |
| Measure | Description | Time Frame |
|---|---|---|
| myocardial damage | Analyse cardiac biomarkers as indicators for myocardial damage: high sensitive troponin (Ths-TrT, ng/mL), creatine kinase (CK, in ng/mL) and creatine kinase-MB isoenzyme (CK-MB, in ng/mL) | patients with that received a coronary artery bypass grafting and that were treated (for approximately 15 days) at the University Hospital between February 2010 and January 2020 (data taken perioperative during hospital stay for CABG) |
| Measure | Description | Time Frame |
|---|---|---|
| 30 days Mortality | death after coronary artery bypass grafting | 30 days after CABG |
| length of stay in the intensive care unit | duration of stay at intensive care unit |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients which underwent isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system) at the department of cardial surgery University Hospital Basel Switzerland
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Oliver Reuthebuch, Prof. Dr. med. | Cardiac Surgery Clinic, University Hospital Basel | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cardiac Surgery Clinic University Hospital Basel | Basel | 4031 | Switzerland |
Not provided
Not provided
Not provided
Not provided
| Cardioplexol | Other | cardioplegia solution |
|
| perioperative during hospital stay for CABG (for approximately 15 days) |
| Number of participants with bleedings | bleeding complication after coronary artery bypass grafting | perioperative during hospital stay for CABG (for approximately 15 days) |
| Number of participants with postoperative arrhythmia | rhythm disturbance after coronary artery bypass grafting | perioperative during hospital stay for CABG (for approximately 15 days) |
| ID | Term |
|---|---|
| D009203 | Myocardial Infarction |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
| D007238 | Infarction |
| D007511 | Ischemia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009336 | Necrosis |
Not provided
Not provided